Medical/Pharmaceuticals

Nippon Express USA Acquires GDP Certification for CFS in Los Angeles and New York

TOKYO, March 8, 2022 /PRNewswire/ -- Nippon Express USA, Inc. (hereinafter "NX USA"), a group company of Nippon Express Holdings, Inc., has obtained Good Distribution Practice (GDP) certification for forwarding operations, inclusive of temporary storage, at temperature-controlled facilities in it...

2022-03-08 14:00 1883

Akeso Announces IND Approval from China NMPA for Phase II Clinical Trial of Cadonilimab in Combination with Docetaxel to Treat NSCLC

HONG KONG, March 7, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso"), a biopharmaceutical company dedicated to the development of innovative antibody drugs, today announced that the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) has approved the IND...

2022-03-08 11:49 1321

WuXi ATU Announces Launch of TESSA™ Technology to Improve Scalability and Accessibility of Cell and Gene Therapies

PHILADELPHIA, March 7, 2022 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the launch of Tetracycline-Enabled Self-Silencing Adenovirus (TESSA™). This technology is a state-of-the-art novel process for transfection-free, scalable manu...

2022-03-08 08:00 1348

Bridge Biotherapeutics Enters into an Option-to-License Agreement with CellionBioMed to Develop BBT-301 for the Treatment of Multiple Fibrotic Diseases

* The company reinforces its strategic focus on fibrotic diseases including idiopathic pulmonary fibrosis (IPF) * Through the option-to-license agreement, Bridge will develop a novel anti-fibrotic ion channel modulator, which is a preclinical candidate SEONGNAM, South Korea, March 7, 2022 /PR...

2022-03-08 08:00 1303

Suvoda Unveils New Brand to Reflect Expanded Focus in Complex Clinical Trial Management

Alongside brand refresh, leading clinical trial technology company announces eConsent and eCOA offerings to better support the patient clinical trial journey. PHILADELPHIA, March 8, 2022 /PRNewswire/ -- Suvoda LLC today launched a refreshed brand, to better reflect its leadership position as a g...

2022-03-08 08:00 1696

Singleron Acquires Proteona

NANJING/SUZHOU, China and COLOGNE, Germany and SINGAPORE, March 7, 2022 /PRNewswire/ -- Singleron Biotechnologies, a leading Chinese genomics company that develops groundbreaking single-cell multi-omics platform technologies and promotes their clinical translations, today announced the acquisitio...

2022-03-07 23:00 1959

Alterity Therapeutics to Present at the 34th Annual Roth Conference

MELBOURNE, Australia and SAN FRANCISCO, March 7, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced thatDavid Stamler, M.D.,...

2022-03-07 20:59 1661

Academic Stress and Emotional Well-Being in Students with Colour Vision Deficiency

KUALA LUMPUR, Malaysia, March 7, 2022 /PRNewswire/ -- Head of Optometry and Vision Science Programme from the Faculty of Health Sciences, Universiti Kebangsaan Malaysia (UKM), Prof DrSharanjeet Kaur Malkeet Singh found that students with congenital colour vision deficiency have emotional problems...

2022-03-07 10:00 3276

HCmed, Formosa Laboratories, and Formosa Pharmaceuticals Signed MoU to Form a Global CDMO for Inhalation Treatment Drugs

TAIPEI, March 7, 2022 /PRNewswire/ -- HCmed Innovations, Co., Ltd. (HCmed) announced that it has formed a strategic alliance with Formosa Laboratories, Inc. (TPEx: 4746) and Formosa Pharmaceuticals, Inc. (TPEx: 6838) to expand its business in the inhalation treatment field, providing contract dev...

2022-03-07 09:00 1956

AnchorDx Appoints Dr. Marina Bibikova as Chief Scientific Officer

GUANGZHOU, China, March 7, 2022 /PRNewswire/ -- AnchorDx, a world-leading developer of cancer screening and early detection solutions, is delighted to announce that Dr. Marina Bibikova has come on board as Chief Scientific Officer (CSO). She will be responsible for cancer early detection technolo...

2022-03-07 09:00 2121

Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 in China for the Treatment of Androgenetic Alopecia in Female Patients

SUZHOU, China, March 6, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment of 160 patients for its...

2022-03-07 08:18 2894

New Robotic Assisted Transperineal Needle-Guidance System for Prostate Biopsy and Cancer Ablations Received U.S FDA 510(k) Clearance

SINGAPORE, March 5, 2022 /PRNewswire/ -- Biobot Surgical is excited to announce U.S. FDA 510(k) clearance of the iSR'obot Mona Lisa 2.0. The new robotic assisted transperineal needle-guidance system allows urologists to plan and position a single needle or multiple needles during image-guided dia...

2022-03-05 20:00 3381

Aravax Pty Ltd announces opening of IND for Phase 2 clinical trials of PVX108, a next-generation immunotherapy for the treatment of peanut allergy

* Phase 2 study of PVX108 to commence in United States and Australia * Dr Robert A. Wood, professor of pediatrics at the Johns Hopkins University School of Medicine, joins Scientific Advisory Board MELBOURNE, Australia, March 4, 2022 /PRNewswire/ -- Aravax, a clinical stage biotechnology compa...

2022-03-04 21:00 2862

111, Inc. Reaches Strategic Partnership on Direct Supply with Beilin Pharmaceutical to Blaze New Trails in Digital Development of Chinese Patent Medicine

SHANGHAI, March 4, 2022 /PRNewswire/ -- On February 23, 2022, 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company inChina, signed a strategic cooperation agreement on direct supply with Xi'an Beilin Pharmaceutical Co., Ltd. ("Beilin Pharmaceutical")...

2022-03-04 17:24 1849

Genome and Company announces Clinical Trial Collaboration with MSD to evaluate 'GEN-001' in combination of KEYTRUDA® (pembrolizumab) in phase 2 clinical trial in biliary tract cancer patients

SEOUL, South Korea, March 3, 2022 /PRNewswire/ -- Genome and Company (KOSDAQ: 314130, CEO∙CTO: Jisoo Pae∙Hansoo Park), a leading global microbiome anti-cancer drug development company, announced it has entered into a first Clinical Trial Collaboration and Supply Agreement (CTCSA) with MSD (a trad...

2022-03-04 09:30 1754

Scientific leaders signal major breakthroughs in elimination of cervical and anal cancers

GENEVA, March 4, 2022 /PRNewswire/ -- To mark International HPV Awareness Day March 4th 2022, the International Papillomavirus Society (IPVS) has warmly welcomed two major advances in the elimination of cervical and anal cancers.

2022-03-04 08:01 2958

Claudin18.2 CAR T Cells (CT041) Receives Approval to Initiate A Confirmatory Phase II Clinical Trial for advanced GC/GEJ in China

SHANGHAI, March 3, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, today announced that the Center for Drug Evaluation (CDE) of the National Medic...

2022-03-03 21:50 1889

I-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific Antibody TJ-CD4B for the Treatment of Gastric Cancer

SHANGHAI and GAITHERSBURG, Md., March 3, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the U.S. Food and Drug Administration (FDA) has gr...

2022-03-03 21:00 1682

CNN's Vital Signs explores the future of medicine

HONG KONG, March 3, 2022 /PRNewswire/ -- From personalized vaccines to lab-grown organs and AI-powered medical devices, the future of medicine is happening right now in labs across the world. This month on CNN's 'Vital Signs' , Chief Medical Correspondent Dr. Sanjay Gupta ...

2022-03-03 10:13 2968

Sequential Skin debuts Sequential Bio - the world's first in-vivo microbiome testing solution for skin, hair, and personal product industries.

LONDON, NEW YORK and SINGAPORE, March 3, 2022 /PRNewswire/ -- Sequential Skin Ltd, a leading microbiome company today announced the debut ofSequential Bio – a novel "in-vivo" microbiome testing solution uniquely tailored for companies across skincare, haircare, and p...

2022-03-03 07:55 2025
1 ... 279280281282283284285 ... 578